Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors


Last updated date
Study Location
Phoenix Children's Hospital
Phoenix, Arizona, 85016, United States


Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center


By email


[email protected]

Call Now

Eligibility Criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Solid Tumors, Ewing Sarcoma, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma
Females and Males
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
2-20 years


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center


[email protected]


Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Solid Tumors, Ewing Sarcoma, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine GliomaStudy Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
  1. Phoenix, Arizona
  2. Baltimore, Maryland
  3. Winston-Salem, North Carolina
  4. Hershey, Pennsylvania
  5. Hershey, Pennsylvania
  6. Seattle, Washington
  7. Birmingham, Alabama
  8. Los Angeles, California
  9. Oakland, California
  10. Orange, California
  11. Palo Alto, California
  12. San Francisco, California
  13. San Francisco, California
  14. Aurora, Colorado
  15. Washington, District of Columbia
  16. Hollywood, Florida
  17. Hollywood, Florida
  18. Saint Petersburg, Florida
  19. Saint Petersburg, Florida
  20. Tampa, Florida
  21. Atlanta, Georgia
  22. Atlanta, Georgia
  23. Indianapolis, Indiana
  24. Louisville, Kentucky
  25. Louisville, Kentucky
  26. Baltimore, Maryland
  27. Boston, Massachusetts
  28. Ann Arbor, Michigan
  29. Ann Arbor, Michigan
  30. Minneapolis, Minnesota
  31. Minneapolis, Minnesota
  32. Minneapolis, Minnesota
  33. Minneapolis, Minnesota
  34. Minneapolis, Minnesota
  35. Jackson, Mississippi
  36. Kansas City, Missouri
  37. Omaha, Nebraska
  38. Hackensack, New Jersey
  39. New Brunswick, New Jersey
  40. New Brunswick, New Jersey
  41. New York, New York
  42. New York, New York
  43. Cincinnati, Ohio
  44. Cleveland, Ohio
  45. Cleveland, Ohio
  46. Columbus, Ohio
  47. Liberty Township, Ohio
  48. Oklahoma City, Oklahoma
  49. Portland, Oregon
  50. Portland, Oregon
  51. Philadelphia, Pennsylvania
  52. Philadelphia, Pennsylvania
  53. Philadelphia, Pennsylvania
  54. Pittsburgh, Pennsylvania
  55. Austin, Texas
  56. Austin, Texas
  57. Dallas, Texas
  58. Houston, Texas
  59. Plano, Texas
  60. Norfolk, Virginia
  61. Richmond, Virginia
2 Years+
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Brief Summary This study will evaluate palbociclib in combination with chemotherapy (temozolomide and irinotecan) in children, adolescents and young adults with recurrent or refractory solid tumors. The main purpose of this study is to evaluate the safety of palbociclib in combination with chemotherapy in order to estimate the maximum tolerated dose. Pharmacokinetics and efficacy of palbociclib in combination with chemotherapy will be evaluated.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:
The study will be conducted of 3 parts: a dose escalation part (following a rolling 6 design), a dose expansion part, and if applicable, tumor-specific expansion part.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Solid Tumors
  • Ewing Sarcoma
  • Rhabdoid Tumor
  • Rhabdomyosarcoma
  • Neuroblastoma
  • Medulloblastoma
  • Diffuse Intrinsic Pontine Glioma
Intervention  ICMJE
  • Drug: Palbociclib
    Administered (oral) at 55 mg/m2, 75 mg/m2, or 40 mg/m2 on days 1-14 of a 21-day cycle
    Other Name: Ibrance
  • Drug: Temozolomide
    Administered at 100 mg/m2 (oral or intravenous), on days 1-5 of a 21-day cycle
  • Drug: Irinotecan
    Administered at 50 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
Study Arms  ICMJE Experimental: Single Arm
Palbociclib in combination with temozolomide and irinotecan
  • Drug: Palbociclib
  • Drug: Temozolomide
  • Drug: Irinotecan
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: October 15, 2018)
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 15, 2024
Estimated Primary Completion Date February 16, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE


  1. For dose escalation part: Histologically confirmed solid tumor (including CNS tumors but not lymphomas). Patients with Diffuse Intrinsic Pontine Glioma do not require histological only radiographic confirmed relapse to enroll
  2. For dose expansion cohort: Histologically confirmed solid tumor including but not limited to Ewing sarcoma, rhabdoid tumor, rhabdomyosarcoma, neuroblastoma, and medulloblastoma.Patients with Diffuse Intrinsic Pontine Glioma do not require histological only radiographic confirmed relapse to enroll
  3. For tumor-specific cohorts: Histologically confirmed solid tumor including but not limited to rhabdoid tumor, rhabdomyosarcoma, neuroblastoma, and medulloblastoma. Patients with Diffuse Intrinsic Pontine Glioma do not require histological only radiographic confirmed relapse to enroll. Ewing sarcoma is not eligible for tumor-specific cohorts.
  4. Age ?2 and <21 years at the time of study entry.
  5. Lansky performance status ?50% for patients ?12 years of age, or Eastern Cooperative Oncology Group (ECOG) 0, 1 or 2 for patients >12 years of age.
  6. Adequate bone marrow function: Absolute neutrophil count ?1000/mm3; Platelet count ?100,000/mm3 (transfusion independent); Hemoglobin ?8.5 g/dL (transfusion allowed);
  7. Adequate renal function (serum creatinine level based on age/gender must be less than or equal to the maximum upper limits specified in protocol)
  8. Adequate liver function, including:Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 × upper limit of normal (ULN) or ?5 × ULN for age, if attributable to disease involvement of the liver; Total bilirubin ?1.5 × ULN for age.
  9. Measurable disease as defined by RECIST version 1.1 or modified RANO criteria for CNS disease or INRC for neuroblastoma.
  10. Recovered to CTCAE Grade ?1, or to baseline, from any non-hematological acute toxicities of prior surgery, chemotherapy, immunotherapy, radiotherapy, differentiation therapy or biologic therapy, with the exception of alopecia.
  11. Serum/urine pregnancy test (for all girls ?8 years of age) negative at screening and at the baseline visit.
  12. Evidence of a personally signed and dated informed consent document indicating that the patient or a legally acceptable representative/parent(s)/legal guardian, for minors, has been informed of all pertinent aspects of the study. Minor study patients also must provide age appropriate assent according to the local guidelines, where applicable.
  13. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other procedures.


  1. Prior treatment with a CDK4/6 inhibitor or progression while on treatment with an IRN-containing regimen that includes TMZ. Patients who have received the combination of IRN and TMZ and did not progress while on these medications are eligible.
  2. Prior intolerability to IRN and/or TMZ.
  3. Use of strong cytochrome P450 (CYP) 3A inhibitors or inducers or strong uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1) inhibitors within 12 days of Cycle 1 Day 1 (C1D1).
  4. Prior growth factors within 7 days before study entry or peg-filgrastim within 14 days before study entry.
  5. Radiation therapy within 14 days before study entry.
  6. Systemic anti cancer therapy within 2 weeks prior to study entry and 6 weeks for nitrosoureas.
  7. Previous high dose chemotherapy requiring stem cell rescue within 90 days or persistent AE >Grade 1.
  8. Prior irradiation to >50% of the bone marrow.
  9. Participation in other studies involving investigational drug(s) within 2 weeks or 5 half lives, whichever is longer, prior to study entry.
  10. Major surgery within 4 weeks prior to study entry. Surgical biopsies or central line placement are not considered major surgeries.
  11. Known or suspected hypersensitivity to palbociclib, IRN and/or TMZ.
  12. Patients with known symptomatic brain tumors or brain metastases and require steroids, unless they have been on a stable or on a decreasing steroid dose for >14 days.
  13. Patients with previously diagnosed brain metastases are eligible if they have completed their prior treatment and have recovered from the acute effects of radiation therapy or surgery prior to study entry for these metastases for at least 14 days post radiation and 4 weeks post-surgery and are neurologically stable.
  14. Hereditary bone marrow failure disorder.
  15. QTc >470 msec.
  16. History of clinically significant or uncontrolled cardiac disease, including: history of or active congestive heart failure; if patient had congestive heart failure resolve and >1 year from resolution, patient will be considered eligible; clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation or Torsades de Pointes); diagnosed or suspected congenital or acquired prolonged QT syndrome; need for medications known to prolong the QT interval; uncorrected hypomagnesemia or hypokalemia because of potential effects on the QT interval; left ventricular ejection fraction <50% or shortening fraction <28%.
  17. Recent or ongoing clinically significant gastrointestinal disorder that may interfere with absorption of orally administered drugs (eg, gastrectomy).
  18. Evidence of serious active or uncontrolled bacterial, fungal or viral infection or known history of hepatitis B virus, hepatitis C virus, or human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness.
  19. Other severe acute or chronic medical or laboratory test abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results, and in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
  20. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  21. Fertile male patients and female patients of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 90 after the last dose of investigational product.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 2 Years to 20 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT03709680
Other Study ID Numbers  ICMJE A5481092
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at:….
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer Call CenterPfizer
PRS Account Pfizer
Verification Date June 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP